title: Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters.
abstract: Treatment with Tositumomab and 131I tositumomab anti-CD20 radioimmunotherapy (Bexxar) yields a nonradioactive antibody antitumor response (the so-called cold effect) and a radiation response. Numerical parameter determination by least-squares (LS) fitting was implemented for more accurate parameter estimates in equivalent biological-effect calculations.
  
  
  METHODS
  One hundred thirty-two tumors in 37 patients were followed using five or six SPECT/CT studies per patient, three each (typical) post-tracer (0.2 GBq) and post-therapy (∼3 GBq) injections. The SPECT/CT data were used to calculate position- and time-dependent dose rates and antibody concentrations for each tumor. CT-defined tumor volumes were used to track tumor volume changes. Combined biological-effect and cell-clearance models were fit to tumor volume changes. Optimized parameter values determined using LS fitting were compared to previous fitted values that were determined by matching calculated to measured tumor volume changes using visual assessment. Absorbed dose sensitivity (α) and cold-effect sensitivity (λp) parameters were the primary fitted parameters, yielding equivalent biological-effect (E) values.
  
  
  RESULTS
  Individual parameter uncertainties were approximately 10% and 30% for α and λp, respectively. LS versus previously fit parameter values were highly correlated, although the averaged α value decreased and the averaged λp value increased for the LS fits compared to the previous fits. Correlation of E with 2-month tumor shrinkage data was similar for the two fitting techniques. The LS fitting yielded improved fit quality and likely improved parameter estimation.
authors.affiliation: 1 Department of Radiation Oncology, University of Michigan , Ann Arbor, Michigan.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Roberson
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Wilderman
authors.forename: Anca M
authors.initials: AM
authors.lastname: Avram
authors.forename: Mark S
authors.initials: MS
authors.lastname: Kaminski
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Schipper
authors.forename: Yuni K
authors.initials: YK
authors.lastname: Dewaraja
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000032:analysis; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D008954:Models, Biological; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000032:analysis; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; C119496:tositumomab I-131